Ciprofloxacin Hydrochloride Premix Veterinary Grade API is the hydrochloric acid monohydrate salt of 1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid, assigned CAS 86393-32-0, molecular formula C17H18FN3O3·HCl·H2O and molecular weight 385.82 g/mol. The substance is a pale yellow to white crystalline powder intended for further processing into tablets, injections, capsules, powders, granules, premix and solutions. Its pharmacological action in veterinary medicine derives from inhibition of bacterial DNA gyrase and topoisomerase IV, with in vitro activity against susceptible Gram-negative aerobes, including Enterobacterales and Pseudomonas aeruginosa; susceptibility interpretation should follow CLSI VET01S or the corresponding regional veterinary breakpoint standard. The monohydrate form is critical to solid-state handling. Dehydration during milling or drying changes crystal habit and may increase electrostatic adhesion to stainless steel contact surfaces. Incoming lots are therefore characterised by powder X-ray diffraction to verify monohydrate content and by Karl Fischer titration per USP <921>; water content is typically held at 3.0–6.0%, consistent with the stoichiometric monohydrate water content of 4.7%. Residual solvents are tested per USP <467>, and the API is released under EU GMP Part II / ICH Q7 conditions. Because ciprofloxacin is a zwitterionic fluoroquinolone with pKa₁ near 6.09 and pKa₂ near 8.74, aqueous solubility is strongly pH-dependent and falls sharply near the isoelectric range between pH 6 and 8. This property controls powder dissolution, liquid formulation, and in vivo absorption when divalent or trivalent cations are present.

The veterinary premix grade is a nonsterile intermediate. Batches intended for sterile injection must be processed further and must meet USP <71> sterility and USP <85> bacterial endotoxins. For solid oral and feed premix applications, microbial limits follow USP <61>/<62>, and elemental impurities are controlled per USP <232>/<233>. Particular attention is given to polyvalent cations because the 4-oxo-3-carboxylic acid pharmacophore chelates Fe³⁺, Al³⁺, Mg²⁺ and Ca²⁺, which can alter dissolution and oral bioavailability. Ciprofloxacin hydrochloride possesses pH-dependent aqueous solubility; at acidic pH the hydrochloride salt dissolves readily, while at neutral and alkaline pH the free base can precipitate. Published data for exact aqueous solubility under feed-matrix conditions is limited.

Which Compendial Specifications Govern Release of the Veterinary Premix Grade?

Table 1 lists the release attributes most relevant to solid oral, liquid and feed premix processing. The values below represent typical harmonised monograph controls; the registered specification may differ by manufacturer and regulatory jurisdiction.

Particle size control for powder and granule intermediates is critical because ciprofloxacin hydrochloride monohydrate is moderately cohesive. Sieve analysis by air-jet method per USP <786> is used for premix and granule cuts; laser diffraction per USP <429> is used for milled fractions. A common premix target is 90% passing 250 µm, but the registered particle-size specification must be matched to the mixing equipment. Over-milling should be avoided because fines below 45 µm above 15% can increase segregation in low-shear tumble blenders and reduce flow through dosator encapsulation machines. Bulk density and tapped density per USP <616> are routine measurements; compressibility index and Hausner ratio per USP <1174> are used to set die-fill and blend-flow parameters. If the angle of repose exceeds 40°, glidant addition or dry granulation is normally required.

Direct Compression Constraints, Granulation Routes, and Tablet Physical Stability

Direct compression of ciprofloxacin hydrochloride is generally limited to low-dose tablets because high drug loads above 50 wt% create die-fill variability, capping and sticking on rotary tablet presses. Production experience on high-speed rotary presses indicates that punch tip temperatures above 40°C increase sticking, especially when magnesium stearate is present below 0.25 wt%. Wet granulation in a top-spray fluid bed with inlet air dew point below 8°C or high-shear granulation with aqueous binder is preferred for robust tabletability. The granulation endpoint is controlled by impeller torque or product temperature, and dried granules are milled through a 1.0 mm rasp screen before compression. Dry granulation by slugging or roller compaction may be used when moisture sensitivity must be minimised, but the thermal and shear input should be controlled because the monohydrate can lose water and alter compaction behaviour.

Dissolution testing for solid oral dosage forms is performed according to USP <711>, using the registered dissolution medium and acceptance criteria. If the formulation includes dicalcium phosphate or other polyvalent cation-containing excipients, chelation may slow dissolution and should be confirmed in the registered media. Tablets containing light-sensitive ciprofloxacin hydrochloride should be coated with an opaque film to reduce photodegradation. Storage in amber HDPE containers with desiccant reduces moisture uptake; at 60% RH the monohydrate remains stable, but open storage in high-humidity tableting suites can increase sticking and picking.

For capsules and oral powders, ciprofloxacin hydrochloride is typically blended with lactose monohydrate or mannitol and a glidant. Over-lubrication with magnesium stearate above 1.0 wt% or mixing longer than 5 min after lubricant addition can suppress dissolution rate; the lubricant should be screened through 500 µm and added to the final blend separately. Encapsulation on tamping pin machines is operated with fill weight RSD below 3.0%; if the blend shows a Hausner ratio above 1.35, pre-compaction or dry granulation is required. Manual filling of powders and granules should be avoided because segregation can produce content uniformity failures under USP <905>.

When Oral Solutions and Injections Demand Acidified, Light-Protected Handling

Because ciprofloxacin is zwitterionic with pKa₁ near 6.09 and pKa₂ near 8.74, aqueous solutions for oral or injectable use are adjusted to pH 3.5–4.5; dilution with neutral or alkaline intravenous fluids can cause precipitation of the free base. Injectable processing generally uses 0.22 µm sterilising filtration followed by aseptic filling, although terminal moist-heat treatment may be acceptable after validation of pH shift and related substances. All liquid presentations are filled into light-resistant containers per USP <671>; photolytic defluorination and piperazine oxidation can increase related substances. Nitrogen purging during filling reduces oxidative discoloration. Bacterial endotoxins per USP <85> must be controlled for parenteral preparations, and particulate matter per USP <788> is monitored in final injectable solutions.

Oral solutions for food-producing animals require withdrawal period data where ciprofloxacin is authorised. Maximum residue limits are regulated by regional authorities, and residue depletion studies must be conducted under GLP. Antimicrobial susceptibility testing should follow CLSI VET01S or regional veterinary breakpoint tables; where ciprofloxacin breakpoints are not published for a given species, enrofloxacin breakpoints are not automatically interchangeable because pharmacokinetic and pharmacodynamic profiles differ.

Premix Carrier Chemistry, Cation Chelation, and Feed Mill Homogeneity

Premix manufacture is the highest risk operation for ciprofloxacin hydrochloride because the API is diluted into carriers that may contain polyvalent cations. The 4-oxo-3-carboxylic acid pharmacophore chelates Fe³⁺, Al³⁺, Mg²⁺ and Ca²⁺; therefore, limestone, dicalcium phosphate, kaolin, bentonite, sepiolite and similar mineral carriers should not be used as premix carriers. Preferred carriers are organic materials such as lactose monohydrate, starch, wheat middlings, corn cob fractions or sucrose. In a production-scale ribbon blender or twin-shaft paddle mixer, the API is triturated stepwise into a small carrier fraction before dilution to full batch size. A coefficient of variation of 5.0% or less across 10 stratified sampling points is a common blend uniformity target. Sampling should follow the stratified procedure described in the FDA Guidance for Industry, Powder Blends and Finished Dosage Units—Stratified In-Process Dosage Unit Sampling, October 2003.

Batch discharge through a bottom slide gate should be controlled because segregation can occur as the bed moves from active flow to funnel flow. Rotary sifters with 850 µm screens are used to break agglomerates before bagging. When medicated feed is pelleted, conditioning temperatures above 70°C and steam addition require stability data specific to the feed matrix; published data for ciprofloxacin hydrochloride stability in high-fat, high-mineral feeds at 60% RH is limited. The finished premix should be packaged in low-permeability paper-plastic laminates and stored below 25°C; open storage in feed mills with condensation cycles must be avoided.

Ciprofloxacin is active at low concentrations in feed. Cross-contamination into non-target feed must be prevented by validated cleaning procedures. Dry vacuum and wiping are preferred for equipment cleanout because aqueous washing may leave residues in dead spaces due to pH-dependent solubility. Residue testing after cleaning should be part of the batch release procedure.

The veterinary premix grade differs from enrofloxacin hydrochloride in that ciprofloxacin is the de-ethylated metabolite and is more hydrophilic, with greater pH-dependent solubility. Enrofloxacin is often preferred in poultry and swine in some jurisdictions because of its established veterinary pharmacokinetic data. Compared with norfloxacin hydrochloride, ciprofloxacin hydrochloride monohydrate has a broader Gram-negative spectrum and a different hydration state. Compared with levofloxacin hydrochloride hemihydrate, the monohydrate water content and drying temperature range differ, requiring separate moisture specifications during granulation. For sterile injectable processing, the grade must meet endotoxin and sterility requirements; for oral powders and granules, particle size and flow are more critical than for solutions. Store in tight, light-resistant containers at 15–30°C, protected from moisture. Do not co-mill with alkaline earth metal salts, and avoid direct contact with strong alkalis; photolytic and strongly oxidative conditions can generate degradation products. Published data for long-term stability in all feed formulations is limited, so each premix must be validated in its final matrix.